Abstract-The patient population benefitting from cardiac implantable electronic devices (CIEDs) is increasing. This study introduces a device annotation method that supports the consistent description of the functional attributes of cardiac devices and evaluates how this method can detect device changes from a CIED registry. We designed the Cardiac Device Ontology, an ontology of CIEDs and device functions. We annotated 146 cardiac devices with this ontology and used it to detect therapy changes with respect to atrioventricular pacing, cardiac resynchronization therapy, and defibrillation capability in a French national registry of patients with implants (STIDEFIX). We then analyzed a set of 6905 device replacements from the STIDEFIX registry. Ontology-based identification of therapy changes (upgraded, downgraded, or similar) was accurate (6905 cases) and performed better than straightforward analysis of the registry codes (F-measure 1.00 versus 0.75 to 0.97). This study demonstrates the feasibility and effectiveness of ontology-based functional annotation of devices in the cardiac domain. Such annotation allowed a better description and in-depth analysis of STIDEFIX. This method was useful for the automatic detection of therapy changes and may be reused for analyzing data from other device registries.
chronization therapy (CRT) devices, which can improve cardiac function in patients with heart failure through the use of synchronous pacing impulses.
National pacemaker registries, such as the French registry STIDEFIX [6] are considered key for data collection and the analysis of cardiac pacing, CRT, and defibrillation therapy, allowing the long-term evaluation of patient prognosis, effectiveness, safety, and costs. Recalls of CIEDs concern hundreds of thousands of patients worldwide, and long-term solutions to this problem include better use of registries and the creation of tools to identify and interpret safety signals [7] .
Data annotation based on the functions of CIEDs would enable comparison of device-replacement procedures and analysis of data in terms of an equivalent, improved, or decreased effect of the therapy delivered to patients. To our knowledge, most national registries rely on proprietary databases with lists of device names, and do not provide straightforward representations of separate CIED functions.
In contrast to the pharmacological domain, where several drug ontologies have been developed and are valuable resources with which to analyze drug prescriptions [8] , no standard resource exists for cardiac device annotation and no ontology has been designed for CIEDs to address the issues of classification, aggregation, and analysis of medical data in pacemaker registries. Moreover, device characteristics cannot be inferred automatically from device names: for example, Medtronic InSync III is a pacemaker with CRT, whereas Medtronic InSync III Marquis is a defibrillator with CRT.
In this paper, we present the first attempt to annotate active medical devices in order to analyze therapy changes in patients from a longitudinal observational database. We describe the creation of an ontology of cardiac devices in OWL-DL, which we then use to represent information on device replacement using data from the STIDEFIX registry. We also report on our use of the ontology in detecting and classifying therapy changes in a cohort of 6905 patients from the STIDEFIX registry.
II. BACKGROUND AND SIGNIFICANCE

A. CIED Therapy
A CIED relies on two essential components: a pulse generator that includes the software and an integrated battery; and leads implanted in the heart cavities and connected to the generator. Different leads may support additional function; moreover, depending on the location of the lead tip, different synchronization patterns will occur while pacing.
Three major CIED kinds of features (we will call them functions in the rest of this paper) are possible: 1) Pacing mode (either ventricular pacing with one lead only or atrioventricular sequential pacing which uses one atrial lead and one ventricular lead). 2) Defibrillation function: in a defibrillator, the lead has special coils (defibrillation electrodes) to allow the device to deliver a high-energy shock, and convert dangerous rapid rhythms (ventricular tachycardia or fibrillation) back to a normal rhythm. 3) CRT function (when resynchronization of the left ventricle is performed by simultaneous pacing by two leads placed, respectively, in the right and in the left ventricle). A change in therapy with respect to those functions requires not only device replacement, but also lead insertion and/or removal or abandon. For example, a pacemaker ventricular lead may not be appropriate for defibrillation and will need to be replaced by a new right ventricular lead that includes a specially designed electrode, if the patient condition would require defibrillation. CRT requires to place the right ventricle pacing lead and then, to advance the left ventricular lead into the coronary sinus branch. The pulse generator can be replaced relatively easily because it is contained in the chest wall pocket and can be reached through a surgical incision. The leads, however, run a long course through the veins into the heart. The removal of such systems is potentially a high-risk procedure, which exposes the patient to increased morbidity risks [9] . For example, each time the lead is separated from a scar tissue, there is a small chance of bleeding in the chest or around the heart.
To replace the battery, the pulse generator must be changed by a surgical procedure every 5 to 10 years. When it is possible, i.e., when there is no major therapy change, implanted leads are preserved and reconnected to the new device. Pulse generators may be replaced with: 1) exactly the same model; 2) a model that is different but is equivalent with respect to the three major functions (the CIED companies produce numerous models and new models may be largely similar to the older devices, with only minor improvements); 3) a model with significantly different functions regarding therapy delivery (in this case, the procedure includes the insertion or removal, or (sometimes) the abandoning of at least one lead in the patient's body). In most cases, rationale is that the patient's clinical condition has evolved in an unexpected way, and needs therapy adjustment.
B. Implantable Cardiac Device in Existing Terminologies, Ontologies, and Standards
As a preliminary step, we evaluated how existing standard terminologies and ontologies cover the concepts required for CIED description. Two medical experts in the CIED domain wrote a list of concepts sufficient to describe the devices and their functions. BioPortal [10] was searched for each concept on the list, and the results were manually reviewed and further defined using terminology browsing where appropriate.
Concept coverage for each of the seven resources is shown in Table I . SNOMED CT, the NCI Thesaurus, and MeSH had the best coverage, but none of them included all the categories on the minimal list of concepts as determined by the domain experts. For example, the entity "artificial pacemaker" was present in SNOMED CT, the NCI Thesaurus, and MeSH, but only the NCI Thesaurus included all types of CIEDs. On the other hand, no device function was represented as such in this ontology, whereas SNOMED CT and MeSH include several essential functions. Moreover, concept descriptions may be controversial; for example, the concept of CRT is present in the NCI Thesaurus, but it represents the act of implanting the CRT device, rather than the therapy delivered by the device itself.
Although the implantable device cardiac nomenclature [11] [12] defines standard terminology for device data, it conveys a summary of information obtained by device interrogation and is not designed to support the description of CIEDs in terms of functionality and comparisons between models.
C. NASPE/BPEG Code
The international coding system NASPE/BPEG generic (NBG) pacemaker code [13] - [15] is used to represent CIED functions in most pacemaker registries, including the French STIDEFIX registry. The NBG coding system has several limitations:
1) It is intrinsically ambiguous: it is not explicit as to whether the code represents the maximal capacity of the device, the mode with which it is programmed, or the mode in which the device is functioning at a given time. All of these entities can be different. For example, an atrioventricular device -DDD-may be programmed in "ventricular pacing only" mode-VVI-in some patients. 2) Several versions of the NBG code have been released. Initially based on a three-digit code, in 1987, it evolved into a five-digit code in 1987. However, as the meaning of the last two digits has changed with time, some NBG identifiers can have different meanings in different versions of the coding system. 3) In 2000, the generic defibrillator code (NBD) coding system was created in 2000 to represent defibrillators, leading to incomplete descriptions of CIEDs when the NBG system is used alone. 4) As a result, a given combination of letters can have a different meaning in different databases or even within the same database, depending on the NBG version. For example, DDDRD can correspond to either a defibrillator, D (dual) meaning pacing and shock or a pacemaker with multisite pacing, D (dual) meaning resynchronization of the atrium and ventricle.
III. MATERIALS AND METHODS
A. Overview of the Method
The annotation and analysis of CIED data from the French national STIDEFIX registry were performed in four steps: 1) data from patients who underwent a pulse-generator change were extracted from the STIDEFIX registry; 2) an ontology of cardiac devices was designed; 3) device models that were present in at least 100 records in STIDEFIX were annotated using this ontology; 4) the functional device annotation based on the ontology was compared with the registry coding on the basis of the therapy change detected by each method.
B. Material 1) STIDEFIX Registry:
The French national registry for pacemakers and defibrillators was created in 1986. The registry, named STIDEFIX, has become increasingly exhaustive since 2005, with physicians obliged to provide clinical and device data for every implanted patient in order to fulfill medical reimbursement requirements [6] . STIDEFIX data are stored in a relational database maintained by the French Society of Cardiology (Société Française de Cardiologie).
The data collected in the STIDEFIX registry include information about pulse generators (i.e., manufacturer, model name, reference, mode, NASPE/BPEG code, polarity, and connection type) and leads (i.e., manufacturer, model name, polarity, and connection type).
2) Data Collection From the Registry: We extracted data from the STIDEFIX registry for all 13684 patients who underwent a device-replacement procedure between July 2006 and October 2010 by using PostgreSQL version 8. 4 .
Data curation consisted of removing records that had identical serial numbers for the old device and the new device, as well as records with inconsistent dates (e.g., when the first device was not explanted on the same day that the second device was implanted).
C. Methods
1) Ontology Design:
We developed the Cardiac Device Ontology (CDO) to support the functional annotation of cardiac devices (e.g., Medtronic Adapta DR is an example of a device that performs two functions: atrioventricular pacing and recording of heart rhythms), and to classify replacement procedures as upgrading, downgrading, or replacement with an equivalent device by detecting whether a prominent function is added, removed, or unchanged compared with the previous device (e.g., if a Medtronic Adapta DR pacemaker is replaced with a Biotronik Lumax HF-T device then CRT and defibrillation functions will have been added and the atrioventricular pacing function left unchanged).
The aims of the CDO are to analyze CIED registries, (i.e., to cluster cardiac devices according to their functional properties) and distinguish between therapy changes and replacement with an equivalent device. In addition, it may be used to detect data inconsistencies and support data quality control.
Design of the CDO included the following steps: 1) Knowledge acquisition of core concepts: We interviewed two electrophysiologists in order to elicit a set of core domain concepts. The same list of concepts established by the experts was also used to evaluate existing terminologies. Each concept was given an unambiguous definition, using appropriate documentation [16] , [17] . In addition, we used two other sources: a) the device features in the different versions of the NBG and NBD codes; b) the upper-level concepts of the ontology developed in the AKENATON project [18] . 2) Formal concept definition: The definitions provided by the medical experts were translated into logical definitions, which led to an Is-A concept hierarchy. Non-Is-A relationships were added when needed (e.g., to link functions and devices). 3) Ontology augmentation: We used a bottom-up approach, starting from lists of manufacturers' products [19] , [20] to ensure that all CIED models could be appropriately defined. New concepts were added where needed. 4) Class creation: Finally, 11 ontology classes that were needed for inference purposes were created. They are described as follows: a) "Patient with function X gained (with X being atrioventricular pacing, defibrillation or CRT). Fig. 1 illustrates the formal definition of the class "patient with CRT gained," defined as a patient who had previously a device with no CRT function and whose new cardiac device supports CRT. b) "Patient with function X lost." c) "Patient with function X idem" (identical).
Those three classes have been created for each function, which lead to nine new classes. They are used to classify the cases and gather the evaluation results directly. d) "Old device" which is used to enter the first device model name. e) "New device" which is used to enter the new (replacing) device model name. We developed the CDO in OWL-DL using Protégé release 4.1. Ontology reasoning tasks were performed using API-OWL version 3.2.2 and HermiT 1.3.3.
2) CIED Annotation: We annotated the CIEDs to the three major functions that are described in Section II-A, and were chosen for their clinical relevance. Each function is characterized by a set of appropriate leads, which means that a change with respect to these functions is associated with significant risks and major modifications in the CIED features.
1) The ability to perform atrioventricular pacing (i.e., "double-chamber" devices). This function requires an atrial lead in addition to the regular ventricle lead. 2) The ability to defibrillate (deliver an electric shock to end a life-threatening arrhythmia). This ability requires a generator with a capacitor, as well as a specific ventricular lead (with an integrated coil, used to deliver the shock).
3) The ability to resynchronize the ventricles, by pacing both walls synchronously. This requires an additional left ventricular lead placed on the epicardial side of the lateral wall of the ventricle. We selected the CIED models with at least 100 occurrences in the STIDEFIX database and represented each one by a class in the CDO. The number of 100 occurrences was chosen to allow the CDO-based analysis of more than 50% of the records in STIDEFIX. Moreover, a majority of the CIED models present in STIDEFIX had less than ten occurrences and, therefore, would be less relevant for statistical analysis.
The device characteristics were extracted from the documentation provided by the manufacturers, manually reviewed by two domain experts, and represented as device properties in the CDO (e.g., Medtronic Adapta DR is a model of a dual-chamber pacemaker; the Biotronik Lumax HF-T device is a model of a CRT defibrillator).
3) Evaluation of Therapy Changes Detection: For each patient, the CDO was populated with data from STIDEFIX. The reasoning capabilities of the CDO were used as follows: 1) three generic individuals, namely patient p, old device x, and new device y, were created in the ontology using OWL-API; 2) we used the HermiT Reasoner [21] to classify the ontology; and 3) we retrieved the inferred classification, including the status of therapy changes, upon the three therapy axis.
For example, patient p has an old device "Medtronic Adapta DR" (atrioventricular pacemaker) and a new device "Biotronik Lumax HF-T" (atrioventricular defibrillator with resynchronization). At the end of the reasoning process, p should be classified in the three following classes: "Patient with CRT gained," "Patient with defibrillation gained," and "Patient with atrioventricular pacing idem."
In order to assess whether using an ontology-based annotation performs better than inferring directly from NASPE/BPEG or equivalent codes in the STIDEFIX registry, we used scripting to detect the same therapy replacements directly from the database. For each patient, we compared the results of the therapy changes detected by the CDO on one hand and NASPE/BPEG on the other hand, first for each function separately and then for the device as a whole (i.e., at least one function was modified versus no change in the three functions).
For example, "Medtronic Adapta DR" is coded as DDD in NASPE/BPEG, which stands for double-chamber pacemaker, whereas "Biotronik Lumax HF-T" is coded as CRT-D, which stands for CRT plus defibrillator. Here, detection of therapy changes by NASPE/BPEG coding would be correct using a direct approach.
IV. RESULTS
A. CDO
The CDO is available as additional material for this paper and can be explored using Protégé editor (downloadable at http://protege.stanford.edu/).
The CDO contains 195 classes organized in three Is-A hierarchies.
1) "Implantable device" is a physical object with subclasses corresponding to the different kinds of devices. 2) "Function" subsumes classes, describing the three major functions defined previously. Two additional classes were created for ontology completeness, namely antitachycardia pacing and cardiac rhythm recording. 3) Patient class and subclasses were used for inference purposes and consisted in the following nine variations: patient with atrioventricular pacing gained/lost/idem, CRT gained/lost/idem, and defibrillation gained/lost/idem. Non-Is-A relations consist of seven properties that were used to link functions and devices (e.g., hasFunction) or to link patients and devices (e.g., IsImplantedBy and its inverse property hasImplant).
Figs. 2 and 3 summarize, respectively, the function classes and the corresponding properties. Fig. 2 summarizes the taxonomical setting of CIED in CDO. It illustrates that despite common medical language, every defibrillator with implanted lead is also a pacemaker (it always has pacing function): CRT-defibrillator, atrioventricular defibrillator, and ventricular defibrillator are subsumed by the corresponding pacing device class. Fig. 3 summarizes the functions defined in CDO. Although the analysis is focused on the three major functions (CRT, atrioventricular pacing, and defibrillation), more features are represented. Antitachycardia pacing is a shockless function based on the use of pacing stimulation techniques for termination of tachyarrhythmia. Such techniques are usually associated with defibrillation. Cardiac rhythm recording is a function present in any device in this version of CDO, represented for completeness.
As seen in the formal definition (see Fig. 4 ), the "St. Jude Medical Anthem" model is defined as a pacemaker with CRT pacing and without defibrillation. As such, it falls under the CRT-P_Device group, which regroups any CRT device without defibrillation. All members of this class have CRT function, as inferred by CDO (yellow highlights, right side in Fig. 4) .
A total of 146 distinct models (17% of all distinct models in STIDEFIX) had at least 100 instances in the STIDEFIX database and were described as a class in the CDO. That list of devices allowed the analysis of 6905 device-replacement procedures (57% of the STIDEFIX registry replacement procedures).
It was possible to cluster the models, after annotation using the CDO, into six distinct superclasses according to their functional characteristics: ventricular-only pacing devices (38 distinct models), atrioventricular pacemakers (55 models), CRT pacing devices (five models), ventricular defibrillators (16 models), atrioventricular defibrillators (17 models), and CRT defibrillators (15 models).
B. Detection of Therapy Changes
The CDO-based identification of therapy changes (upgraded, downgraded, or similar) performed perfectly compared to analysis of NASPE/BPEG codes, when each of three functions was analyzed separately (F-measure 1.0 versus 0.75 to 0.97), as well as for detecting at least one function change versus no change at all (F-measure 1 and 1 versus 0.82 and 0.95). These results are summarized in Table II . NASPE/BPEG analysis performed statistically better for atrioventricular pacing, which is consistent with the fact that this coding system was originally designed to describe atrioventricular versus atrial or ventricular pacing.
The total duration of CDO processing, including instance creation, reasoning, and retrieving data, was 53 min 54 s (OS: Windows 7, CPU Intel Core i3 3.2 GHz, 4-GB RAM), resulting in mean duration of 468 ms/ patient. NASPEE/BPEG processing was not measured in detail but was shorter, in regard of fewer computational steps. In terms of misdetection of therapy changes, using NASPE/NBG coding alone resulted in at least one error in 533 patients (7.7% of 6905 patients). Most errors were due to the missing code in the database (83%) and the latter 17% were improper coding (wrong code for the specified model); interestingly, a total of 103 patients had coding errors implying three unique device models. 1) St. Jude Medical Victory DR was coded as a CRT-P device (CRT pacemaker) instead of an atrioventricular pacemaker (DDD). 2) St. Jude Medical Frontier II was coded as an atrioventricular pacemaker instead of CRT-P. An inversion in the model list is likely to have caused the two errors mentioned previously, but this hypothesis could not be confirmed. 3) Biotronik Lumax VR-T was classified as a pacemaker instead of a defibrillator.
C. Clinical Results
We present hereafter some results on the basis of the clinical relevance in terms of unexpected therapy changes in STIDE-FIX patients. A total of 867 patients (12.6%) had at least one additional lead inserted during device replacement, which took place 3.89 years after the previous device was implanted. A total of 550 of these (8%) were left ventricular leads (for CRT), 220 (3.2%) were right atrium leads (for atrial pacing), and 227 (3.3%) were ventricular leads (mostly defibrillation leads). A total of 660 patients (9.6%) had at least one lead abandoned or explanted during device replacement. These data will be described further and discussed in a subsequent paper.
V. DISCUSSION
A. Strengths and Limitations of an Ontology-Based Approach for Functional Annotation of Cardiac Devices
Data repositories in the domain of CIED therapy are still limited, especially when compared with the pharmacological domain. However, pacemaker registries provide a large data source upon which decisions concerning the current state of pacing can be made.
We have demonstrated that analysis of device registry data can be made easier by annotating devices to an ontology. A limitation of this study is that, in the case of CRT devices, atrioventricular pacing is always possible. As a consequence, when switching from or to a CRT device, one cannot be sure that the atrioventricular function was used unless one knows if an atrial lead was physically connected to the pulse generator. To address that issue, we are currently working on extending our ontology to device parts such as leads (lead data are present in some registries, including STIDEFIX).
In this study, our ontology-based approach performed better than a straightforward approach based on preexisting codes. This was due to several factors. First, the NASPE/BPEG coding system has become ambiguous over time as a result of new device functions. We believe that this phenomenon is not domainspecific and that unanticipated technological breakthroughs in medical devices will cause more coding inconsistencies. Second, the ontology helped to present device models as groups of devices sharing the same functions. The work presented in this paper is a first step toward a controlled vocabulary for describing CIED characteristics and cardiac device annotation data, as well as toward tools to access and process this data.
B. Reusability and Perspectives
One major issue raised by ontologies is the reusability issue [22] . Our approach combined a formal definition of concepts, reuse of upper-level classes from a preexisting foundational ontology, and mapping to the models in manufacturers' lists; we believe that this approach enables optimal reusability of this ontology for other devices in the same domain, as well as for other domains. New device functions can easily be added to the function axis, and new models can easily be represented. However, because of the open-world assumption in OWL-DL, it is crucial to add closure axioms (i.e., to assume that the functions associated with the model in the ontology are the only functions that the model can perform).
This also raises maintenance issues for the device functions: when a new function is added to the ontology, all device descriptions must be updated with the new characteristic. This updating will be facilitated by our classification of the models in a taxonomy composed of six classes. Moreover, formal function definition is expected to help versioning. For instance, Reveal is a cardiac monitoring device that can be implanted to record arrhythmias [23] . It was not present in the STIDEFIX database, but it would be easy to represent it within the ontology as a nonpacing and cardiac-recording-only device. The cardiac rhythm recording function is already performed by pacing devices, and thus, the corresponding concept is present in the ontology and is reusable to annotate Reveal.
We evaluated the CDO using a French registry, but it can be used to annotate and analyze other data repositories within the same domain. Ideally, as in other domains (e.g., genomics, with the HUGO gene nomenclature and gene ontology annotation), efforts to promote standard naming of model devices should accompany ontology efforts. This normalization issue is currently being discussed in IEEE and IHE working groups, and a standard that may support better normalization for naming models is expected to emerge soon [24] .
Extending the CDO to other medical devices would require that the same formal definition steps be taken. We believe that our method gives guarantees in favor of extensibility. We have emphasized the basic "ontological" separation between a physical object and a function it bears; this distinction will be effective in representing most therapeutic devices and sensors. The objective of standardization for sensors and observations is shared with recent works from the world wide web consortium, whose technological choices were consistent with ours [25] .
C. Device Annotation and Medication Annotation are Useful to Evaluate Therapy
To our knowledge, a CIED ontology has not previously been developed; by contrast, several ontologies are available for pharmaceutical drugs (e.g., RxNorm [26] ). These include formal representation of drug properties, such as chemical structure, cellular or subcellular mechanisms of action, organ-or systemlevel physiologic effects, therapeutic intent, and pharmacokinetics [8] . Each drug is annotated using a list of attributes describing these properties in order to support tasks, such as drug substitution. Drug substitution involves replacing a drug with another that is identical (e.g., Cardene instead of Loxen, both commercial forms of nicardipine). Other uses for such ontologies involve identifying suitable combinations of drugs after the failure of monotherapy; for example, combined therapy with lisinopril and hydrochlorothiazide may be proposed when blood pressure control cannot be obtained using lisinopril alone. To aid the identification of functionally equivalent drugs, and increases or decreases in drug therapy, it is crucial that pharmaceutical ontologies enable meaningful semantic comparisons between different drugs.
Similarly, we designed an ontology for cardiac devices to support the analysis of device replacement, including the distinction between switching to a new device with similar attributes and switching to a device with upgraded or downgraded characteristics. This ontology is expected to provide clear and formal device descriptions to support medical decision making, as well as to help with classifying, aggregating, and finally analyzing data from device registries. We expect this will lead to a better understanding of the impact of CIED functions on patient prognosis, and hence allow better a priori selection of devices based on individual patient clinical data.
VI. CONCLUSION
We have designed an ontology that enables the functional annotation of CIEDs. We have shown that ontology-based functional annotation of medical devices is feasible and useful, and performs better than straightforward exploitation of CIED codes for analyzing registry data. We annotated a set of devices that covered more than 50% of cardiac device replacements within a database. This approach may be extended to other devices, including therapeutic devices outside the cardiology domain.
